1 day Ago By ABMN Staff
Stock analysts at StockNews.com initiated coverage on shares of Revance Therapeutics ( NASDAQ:RVNC – Get Free Report ) in a report released on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
RVNC has been the topic of several other reports. Piper Sandler lowered shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 12th. Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a research report on Monday, August 12th.
Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Stifel Nicolaus decreased their price target on Revance Therapeutics from $24.00 to $20.
00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Finally, William Blair reaffirmed a “market perform” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Nine investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock.
According to MarketBeat.com, Revance Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $9.66.
Read Our Latest Research Report on Revance Therapeutics Revance Therapeutics Trading Down 5.8 % Revance Therapeutics ( NASDAQ:RVNC – Get Free Report ) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.
37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02).
The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million.
On average, sell-side analysts predict that Revance Therapeutics will post -1.54 EPS for the current year. Institutional Investors Weigh In On Revance Therapeutics Hedge funds have recently modified their holdings of the company.
LMR Partners LLP acquired a new position in shares of Revance Therapeutics in the third quarter valued at approximately $11,648,000. Capital World Investors lifted its stake in shares of Revance Therapeutics by 16.8% during the 1st quarter.
Capital World Investors now owns 13,945,535 shares of the biopharmaceutical company’s stock worth $68,612,000 after purchasing an additional 2,006,459 shares during the period. Integral Health Asset Management LLC acquired a new stake in shares of Revance Therapeutics during the second quarter worth $1,285,000. Vanguard Group Inc.
grew its position in shares of Revance Therapeutics by 6.5% in the first quarter. Vanguard Group Inc.
now owns 5,398,406 shares of the biopharmaceutical company’s stock valued at $26,560,000 after purchasing an additional 328,781 shares during the period. Finally, Blair William & Co. IL increased its stake in Revance Therapeutics by 3.
6% in the first quarter. Blair William & Co. IL now owns 329,267 shares of the biopharmaceutical company’s stock valued at $1,620,000 after purchasing an additional 11,318 shares during the last quarter.
97.70% of the stock is owned by institutional investors and hedge funds. About Revance Therapeutics ( Get Free Report ) Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.
The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. See Also Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
